PULSE BIOSCIENCES, INC.
Nasdaq · Surgical & Medical Instruments & Apparatus
Company Overview
A concise company profile alongside the latest public filing activity.
Pulse Biosciences develops medical technology based on its proprietary Nanosecond Pulsed Field Ablation (nsPFA) platform, which uses short electrical pulses to destroy targeted tissue without heat-related damage. The company is focused on applications in cardiac arrhythmia treatment and other soft tissue ablation procedures.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Teplitsky Liane RaeChief Operating Officer | Buy | $50K | 1,034at $48.35 | Aug 28, 2026 |
| Teplitsky Liane RaeChief Operating Officer | Buy | $50K | 1,036at $48.23 | Aug 26, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PLSE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.